Genomic imaging for precision medicine
FORWARD LOOKING STATEMENTS

This presentation contains “forward-looking information” within the meaning of applicable securities laws in Canada, including statements about 3D Signatures’ business and corporate strategy, product utility, development and performance, regulatory matters, manufacturing plans and intellectual property plans and the expected development of 3D Signatures’ business, trials, products, projects and partnerships. Particularly, information regarding our expectations of future results, performance, achievements, prospects or opportunities is forward-looking information. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or variations of such words. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. For this purpose, any statement that is not a statement of historical fact should be considered forward-looking information.

Forward-looking information contained in this presentation is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct.

Forward-looking information is also subject to numerous risks and uncertainties, including: 3D Signatures’ short operating history; the possibility that 3D Signatures may never receive any product sales revenue or achieve profitability; risks involved in completing the clinical development of, and receiving regulatory approval for, our product candidates; uncertainties related to whether our product candidates under development will become effective diagnostics; as well as those risks and uncertainties discussed under “Part 1 - Risk Factors” in 3D’s Filing Statement, dated August 22, 2016 and available on the Company’s SEDAR profile at www.sedar.com. Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to us, or that we presently believe are not material, that could also cause actual results or future events to differ materially from those expressed in the forward-looking information in this presentation.

There can be no assurance that the forward-looking information in this presentation will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. The forward-looking information contained in this presentation represents our expectations as of the date of this presentation or the date indicated, regardless of the time of delivery of the presentation. 3D Signatures undertakes no obligation to update the forward-looking information in this presentation except as required by applicable law. All of the forward-looking information contained in this presentation is expressly qualified by the foregoing cautionary statements.
Unlike most diagnostic companies, our proprietary imaging software goes beyond identifying whether a patient suffers from a specific disease or condition.

Our analytics platform tells doctors how to personalize treatment and best manage the disease for each individual patient.
EXTENSIVELY DEVELOPED PLATFORM

20+ years of research

$25M+ in non-dilutive R&D funding

130+ peer-reviewed papers

14 diseases

2,000+ patients

22 clinical studies
3D Telomere Analysis is a **disruptive** technology based on a **universal** structural biomarker.
DNA is packaged into chromosomes.

At the tips of each chromosome are protective regions of DNA called telomeres.

Using fluorescent markers and high resolution microscopes, the location of each telomere within a cell nucleus can be visualized and digitally analyzed.

The 3D organization of telomeres within a given cell is highly predictive of the disease status of the patient.

3D telomere organization is a highly accurate, universal biomarker.
ENABLING TRULY PERSONALIZED MEDICINE

Who has a particular disease

How stable is the patient’s genome

How aggressive is the disease

How will the patient respond to treatment
OPPORTUNITY
WELL-PROTECTED
NORTH AMERICA AND EUROPE

Intellectual Property includes **16 issued or pending patents** in the United States, Canada and Europe.

Includes prognostic, risk, predictive and monitoring tests for multiple cancers and diseases, including:

- Hodgkin’s Lymphoma
- Prostate Cancer
- Multiple Myeloma
- Alzheimer’s Disease
- Blood Cancers
- Several Other Cancers
<table>
<thead>
<tr>
<th>Title</th>
<th>Layman Description</th>
<th>Country and Number</th>
</tr>
</thead>
</table>
| Method of Monitoring Genomic Instability Using 3D Microscopy and Analysis | Prognostic, risk predictive and monitoring test for several cancers                | Canada National Phase; 2515792  
USA National Phase; 7801682 – Issued Sept 2010  
Europe National Phase; EP047134994 – Issued Dec 2015 |
| Methods of Detecting and Monitoring Cancer Using 3D Analysis of Centromeres | Prognostic, risk predictive and monitoring test for several cancers                | Canada National Phase of; 2665100 – Issued June 2016  
USA National Phase; 8849579 – Issued Sept 2014  
Europe National Phase; EP07815918.3 – Issued Nov 2015 (Validated in UK, Germany & France) |
| Diagnostic Methods for Hematological Disorders                       | Prognostic and risk predictive test for blood cancers                           | Canada National Phase; 2760873  
USA National Phase; 692645                                                   |
| Methods for Diagnosing Alzheimer’s Disease                           | Prognostic and risk predictive test for Alzheimer’s disease patients             | Canada National Phase; 2895211  
USA National Phase; 14/365141  
Europe National Phase; EP12857141.1                                          |
| Methods for Evaluating Alzheimer’s Disease and Disease Severity       | Prognostic and risk predictive test for Alzheimer’s disease patients             | Canada National Phase; 2856419  
USA National Phase; 14/491,996                                                  |
| Method for Characterizing and Isolating Circulating Tumour Cell Subpopulations (Prostate Cancer) | Prognostic and risk predictive test for Prostate Cancer patients               | Canada National Phase; 2775315  
USA National Phase; 13/869797                                                   |
| Diagnostic Methods Using Granulometry                                | Prognostic, risk predictive and monitoring for several cancers by examining DNA-occupied territories inside the cell/nucleus | USA National Phase; 14/852143                                                  |
WHAT WE DO

1. SAMPLE COLLECTION
   Tissue, lymph node aspirates, blood, bone marrow, buccal swab collection

2. THREE-DIMENSIONAL TELOMERE-FISH ASSAY
   Preservation of 3D nuclear structure and labelling of telomeres

3. THREE-DIMENSIONAL IMAGE ACQUISITION
   Automated z-stack acquisition of different focal planes of single nuclei

4. IMAGE EXPORT
   Reconstructed 3D images exported as .TIFF to centralized 3DS analytics centre

GLOBAL CLINICAL LAB PARTNERS 3DS LAB
WHAT WE DO

5
TELOVIEW™ IMAGE ANALYSIS

1. Number of telomere signals
2. Signal intensities
3. Number of telomere aggregates
4. Distribution of telomeres within nuclei
5. Position of telomeres relative to the center and periphery of nuclei
6. Nuclear volume

6
SCORING MODEL

Scoring model based on the parameters generated by TeloView™ image analysis

7
PERSONALIZED MEDICAL REPORT TO CLINICIAN

SCREENING
Who has a particular disease

DIAGNOSIS
What kind of disease/cancer

PROGNOSIS
How stable or aggressive is the disease/cancer

PREDICTING
How will the patient respond to a specific treatment

MONITORING
Whether the patient is stable over the course of treatment/disease

DRUG DEVELOPMENT
Enabling pharma companies to identify and develop better drugs
3D Signatures will charge a fee for every test which creates a sustainable SaaS business model.

The analytics platform is highly scalable.

Core intellectual property will not leave the Company’s server.
UNIVERSAL STRUCTURAL BIOMARKER

Hodgkin’s Lymphoma
Prostate Cancer
Multiple Myeloma
Alzheimer’s
Thyroid Cancer
MDS/ML
Glioblastoma
Cholangiocarcinoma
Breast Cancer (TNBC)
Ependymoma
Esophageal Cancer
Neuroblastoma
NSC Lung Cancer

Unique 3D telomere signatures found to correlate with various stages and forms of the disease
## PRIORITY PIPELINE

<table>
<thead>
<tr>
<th>TARGET</th>
<th>TEST</th>
<th>RESEARCH</th>
<th>DEVELOPMENT</th>
<th>VALIDATION</th>
<th>MARKET</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hodgkin's Lymphoma</td>
<td>3D Telo-HL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate Cancer</td>
<td>3D Telo-PC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>3D Telo-MM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer's</td>
<td>3D Telo-AD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>3D Telo-LC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Physicians cannot predict whether a patient will respond to standard chemotherapy and enter long-term remission or not respond and relapse, usually within 24 months.
These patients can receive optimized treatments at the outset, resulting in:

- New Treatment Options
- Reduced Complications
- Significant Cost Savings
- Shortened Treatment Cycles

20% of patients with Hodgkin’s Lymphoma will not respond to standard chemotherapy.
The ability to determine which prostate cancer patients should be prioritized for treatment and determining which treatment would be a true game changer.

~30 million men are screened for prostate cancer each year

180,000 will be diagnosed annually

26,000 will die of the disease

10.7% of all new cancer cases are diagnosed as prostate cancer

~$15B spent annually diagnosing and treating prostate cancer

Currently, patients face the choice of living with cancer under active surveillance or pursuing treatment that is highly efficacious, but accompanied by significant risk of side effects and complications.

<table>
<thead>
<tr>
<th>SIDE EFFECT*</th>
<th>PROSTATECTOMY</th>
<th>RADIOTHERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>URINARY INCONTINENCE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No control or frequent urinary leakage</td>
<td>10%</td>
<td>3%</td>
</tr>
<tr>
<td>Bothered by dripping or leaking urine</td>
<td>11%</td>
<td>2%</td>
</tr>
<tr>
<td><strong>BOWEL DYSFUNCTION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bowel urgency</td>
<td>14%</td>
<td>34%</td>
</tr>
<tr>
<td>Frequent bowel movements, pain, urgency</td>
<td>3%</td>
<td>8%</td>
</tr>
<tr>
<td><strong>SEXUAL DYSFUNCTION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erectile insufficient for intercourse</td>
<td>79%</td>
<td>61%</td>
</tr>
<tr>
<td>Bothered by sexual dysfunction</td>
<td>56%</td>
<td>48%</td>
</tr>
</tbody>
</table>

3D Telo-PC

Liquid Biopsy designed to stratify patients and predict most effective treatment plan
INVESTMENT HIGHLIGHTS

1. DISRUPTIVE TECHNOLOGY
   - Proprietary 3D imaging technology could represent a major medical advancement in patient diagnosis, treatment and the development of companion diagnostics to personalize patient treatment.

2. SOFTWARE AS A SERVICE (SAAS) BUSINESS MODEL
   - Building a highly scalable SaaS based business with high margins and low overhead.
   - Proprietary software never leaves the Company’s server while raw digital data can be collected and analyzed from partner labs located around the world.

3. ATTRACTION INDUSTRY MAJORS
   - Highly promising and unconventional software platform is already attracting attention from multinational healthcare companies relatively early in the product development process.

4. EXPERT TEAM WITH SUCCESSFUL TRACK RECORD IN BIOMEDICAL MARKET
   - Accomplished leadership with ability to develop and commercialize new products and secure strategic partnerships.

5. EXCEPTIONAL TIMING AHEAD OF IMPORTANT CATALYSTS
   - Steady stream of positive news flow expected including talent acquisition, clinical trial progress and new business developments.

6. FISCAL MANAGEMENT
   - Drive growth through strategic allocation of capital.
   - Control expenses through sensible fiscal management and streamlined operations.
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Background Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Swift, LLB</td>
<td>Chair, Board of Directors</td>
<td>Past Principal Secretary in the Prime Minister’s Office and Chief of Staff, Office of the Leader of the Opposition, Government of Canada. Past board member of GenXys Health Care Systems, Inex Pharma, Ultrasonix Medical Corp. and Neurmed Technologies Inc. Past Chairman of Central City Foundation.</td>
</tr>
<tr>
<td>Jason Flowerday</td>
<td>CEO &amp; Director</td>
<td>Mr. Flowerday has extensive life sciences leadership experience including over a decade of business development and marketing work for two of the world’s largest pharmaceutical companies, Germany’s Bayer AG and US-based Johnson and Johnson. Other notable positions include executive leadership and entrepreneurial roles with Knight Therapeutics and Pro Bono Bio Inc. Mr. Flowerday was also co-founder and co-owner of both Orphan Canada and RxMedia Healthcare Communications. He is an independent Director of Aequus Pharmaceuticals.</td>
</tr>
<tr>
<td>Dr. Sabine Mai, PhD</td>
<td>Director and Chair, Clinical and Scientific Advisory Board</td>
<td>Dr. Sabine Mai is currently Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science, University of Manitoba. She is also Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at University of Manitoba.</td>
</tr>
<tr>
<td>Ferenc Somogyvari</td>
<td>Director</td>
<td>Co-founder and former GM of Carl Zeiss Microscopy with more than 38 years in the optical medical and biology industries. Former CEO of 3D Signatures.</td>
</tr>
<tr>
<td>Helen Stevenson</td>
<td>Director</td>
<td>Helen Stevenson is Founder and Chief Executive Officer of Reformulary Group Inc., a company dedicated to helping manage prescription drug costs for employer drug plans while promoting better patient health outcomes. Ms. Stevenson was formerly Executive Officer of Canada’s largest provincial drug program, the Ontario Public Drug Program by Order-In-Council, as well as Assistant Deputy Minister at the Ontario Ministry of Health and Long-Term Care.</td>
</tr>
<tr>
<td>Bruce Colwill</td>
<td>Director</td>
<td>Strategic finance professional with over 25 years of experience in start-up and entrepreneurial companies. As the CFO of multiple public and private companies, Bruce has been responsible for fundraising in excess of US$400 million including private and public financing, debt and other structured financings. He holds a BBA from Simon Fraser University and is a Canadian Professional Accountant (CPA, CA).</td>
</tr>
<tr>
<td>Gordon McCauley</td>
<td>Director</td>
<td>President and CEO of Viable Healthworks Corp. and Chairman of Life Sciences BC. Co-founder and former President and COO of Neuro Discovery Inc. (NDI Capital). Past President and CEO of Allon Therapeutics.</td>
</tr>
</tbody>
</table>
### Jason Flowerday  
**CEO & Director**

Mr. Flowerday has extensive life sciences leadership experience including over a decade of business development and marketing work for two of the world’s largest pharmaceutical companies, Germany’s Bayer AG and US-based Johnson and Johnson. Other notable positions include executive leadership and entrepreneurial roles with Knight Therapeutics and Pro Bono Bio Inc. Mr. Flowerday was also co-founder and co-owner of both Orphan Canada and RxMedia Healthcare Communications. He is an independent Director of Aequus Pharmaceuticals.

### Joost van der Mark  
**Chief Business Officer**

Mr. van der Mark is a seasoned healthcare executive with over two decades of experience in the biopharmaceutical industry and joined 3D Signatures as Chief Business Officer responsible for business development. Prior to joining 3D Signatures, Mr van der Mark served as the Vice President of Corporate Development of BioSyent Inc. responsible for the acquisition and licensing activities for the corporation. Mr van der Mark was co-founder and co-owner of Orphan Canada Inc. prior to it’s sale to Knight Therapeutics and prior to this had progressive positions at Nycomed (Takeda), Sanofi Pasteur and Bayer. Mr. van der Mark holds an M.Sc. in Physiology and Pharmacology from the University of Western Ontario and an M.B.A. from Schulich School of Business.

### Hugh Rogers, LLB

**VP, Corporate Finance**

Leader in business management, regulatory compliance, finance and investor relations for private and public companies within health sciences, digital technology and resource industries. He is a director of MCorpCX Inc. and Coronado Resources Ltd.

### Omar Samassekou MD, PhD

**VP, Clinical Programs**

Trained in medical genetics, cytogenetics and other molecular genetics with expertise in prenatal diagnosis and cancer genomics. Involved in development of non-invasive diagnostic procedure to detect fetal chromosomal abnormalities from maternal peripheral blood.

### Keith B. Cassidy

**Chief Financial Officer**

Strategic health care, legal services and education leader. Former Executive Director for multiple law firms and former VP Finance and CFO for the Royal Victoria Hospital.
Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School, as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at Johns Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.

Dr. Klotz is internationally recognized for his contributions to the treatment of prostate cancer, notably for pioneering the adoption of Active Surveillance as a standard aspect of patient care. Dr. Klotz obtained his medical degree and residency training from the University of Toronto with a special fellowship in uro-oncology and tumour biology at Memorial Sloan Kettering Cancer Centre, New York. He is a widely published uro-oncologist who serves on the board or heads many medical/scientific organizations. He is a Professor, Department of Surgery, University of Toronto, past Chief of Urology, Sunnybrook Health Sciences Centre, Toronto, and Chairman, World Uro-Oncology Federation. Dr. Klotz was awarded the Order of Canada in 2014 for his contribution to prostate cancer treatment.

Dr. Knecht established himself as a prominent haematologist through his ground-breaking translational research on lymphoma biology. His current focus is on the molecular events leading to the transition from the mononuclear Hodgkin to the multinuclear Reed-Sternberg cell and the impact of 3D nuclear telomere organization on this transformation. Dr. Knecht received his medical degree from the University of Zurich, Switzerland with post-graduate work under both Maxime Seilgmann (Haematology) and Karl Lennert (Haematopathology) in Paris and Kiel, respectively. Dr. Knecht is currently a Professor of Medicine and Chief, Division of Haematology at McGill University and Jewish General Hospital, Montreal.
Darrel Drachenberg, MD

Dr. Drachenberg is a urologic oncologist and researcher and strong proponent of Active Surveillance for prostate cancer patients. Dr. Drachenberg attended medical school at the University of British Columbia and urology residency at Dalhousie University. He is an American Foundation of Urology Scholar with fellowship training in urologic oncology at the National Cancer Institute in Bethesda, Maryland. He founded the laparoscopic urology program and prostate brachytherapy, cryotherapy, and HIFU programs at the University of Manitoba where he works as assistant professor of surgery and director of research for the Manitoba Prostate Center and Section of Urology and Chair of the Genito-Urinary disease site group, CancerCare Manitoba.

Rami Kotb, MD

Dr. Kotb completed his medical residency training in Paris, France, and then became a staff member at Paris XI University. He joined the Hematology-Oncology team at Sherbrooke University (QC, Canada) in 2005 as an Assistant, then Associate Professor. He also worked as the Director of Hematology undergraduate education, Head of the supra-regional team of Hematological Neoplasia and Head of the Institutional Oncology Quality Sub-committee. Late 2011, he moved to British Columbia to work at the BC Cancer Agency as an Oncologist/Hematologist, Associate Professor at the University of British Columbia and affiliate Professor at the University of Victoria. He joined the team at CancerCare Manitoba in September 2014. His practice and research activity will be focused on lymphoid neoplasia, primarily myeloma and lymphoma.

Thomas Cremer, MD

Dr. Cremer is an internationally-recognized scientist specializing in the studies of nuclear architecture. He is one of the pioneers of interphase cytogenetics and comparative genomic hybridization (CGH). These methods have become widely used tools for cytogenetic analyses of chromosomal imbalances. He is a corresponding member of the Heidelberg Academy for Sciences and Humanities since 2000, a member of Germany’s National Academy of Sciences Leopoldina since 2006, an honorary member of both the European Cytogenetics Association (ECA) and the German Society of Human Genetics since 2011, as well as the recipient of the medal of Honor of this Society. Dr. Cremer is an independent expert to 3DS.

Ian Smith, PhD

Dr. Smith, OC, PhD, DSc, FRSC, is currently the Chairman of the Centre for Imaging Technology Commercialization. His past research and commercialization achievements include significant success in the field of magnetic resonance imaging. Dr. Smith is a former Director General of the NRC Institute for Biological Sciences, Ottawa, ON, and founder and Director General of the Institute for Biodiagnostics, Winnipeg, MB. He is a passionate advocate for the advancement of diagnostics for the early detection and treatment of disease.
BUSINESS ADVISORY BOARD

Jonathan Goodman
Director & CEO,
Knight Therapeutics Inc.

Prior to Knight, Mr. Goodman was the co-founder, President and CEO of Paladin Labs Inc. which was acquired by Endo for $3.2 billion. Under his leadership, $1.50 invested in Paladin at its founding was worth $142 nineteen years later. Prior to co-founding Paladin in 1995, Mr. Goodman was a consultant with Bain & Company and also worked in brand management for Procter & Gamble. Mr. Goodman holds a B.A. with Great Distinction from McGill University and the London School of Economics with 1st Class Honours. Additionally, Mr. Goodman holds an LL.B. and an M.B.A. from McGill University.

Dr. Heiner Dreismann
Past President and CEO,
Roche Molecular Diagnostics

Dr. Dreismann is a seasoned executive with more than 24 years experience in the healthcare industry, and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique, one of the most ubiquitous technologies in molecular biology and genetics research today. He had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO, Roche Molecular Systems, Head of Global Business Development, Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfälische Wilhelms University (The University of Munster) in Germany.

John Lindsay
Founder, SciPartners

Mr. Lindsay began his career at Millipore Corporation, Merck KGaA, and quickly advanced to become the youngest Vice President in the history of the company. He was promoted to Executive Vice President of several divisions, including the Analytical Group and Milligen Biosearch Divisions. In 2000, he founded SciPartners, with the objective of building a platform for development of early stage European and North American firms. His focus is the Life Science market, and over the past 14 years he has successfully built up sales and marketing that led to rapid growth and increased revenues for many companies, and the acquisition of ProXeon by ThermoFisher and the acquisition of Halo Genomics by Agilent.

Nigel Terrett
As chairman of the board of Excelleris Technologies, Mr. Terrett led the creation of the largest integrated patient and physician diagnostic database in Canada. During his tenure as chief strategic officer of Life Labs, he created innovative collaborative programs with health institutions, provincial governments and health providers to improve health care while reducing costs. As senior vice-president and general manager of Life Labs British Columbia, Mr. Terrett was responsible for 900 operational staff, 90 branch locations and two state-of-the-art medical laboratories providing over 15 million medical results per year. As chief information officer of MDS Diagnostics, he led the restructuring of information technology services that resulted in multimillion-dollar savings for the company. During his tenure as vice-president of information technology at MDS Diagnostics, Mr. Terrett led a North American team that increased operating income by over 50 per cent.

Harry Glorikian

Mr. Glorikian has over 30 years of private and public company success in the biomedical and life sciences industries and is a recognized global innovator in the field of medical diagnostics. Recent experience includes roles as Entrepreneur in Residence to GE Ventures – New Business Creation Group and as a member of the board of directors of GeneNews Ltd. He also serves on the advisory board of Nuclis and Evidation Health. Mr. Glorikian is also a co-founder and an advisory board member of DrawBridge Health. Previously he co-founded and held the position of managing director and head of consulting services for Scientia Advisors which was acquired by Precision for Medicine in 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories.
### PRO-FORMA CAPITAL STRUCTURE

<table>
<thead>
<tr>
<th>3D Signatures</th>
<th>TSX.V: DXD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issued &amp; Outstanding Shares</td>
<td>52,828,756</td>
</tr>
<tr>
<td>Escrowed Shares (3 Year Matrix)</td>
<td>16,783,964</td>
</tr>
<tr>
<td>Warrants</td>
<td>7,624,838</td>
</tr>
<tr>
<td>Options</td>
<td>5,121,081</td>
</tr>
<tr>
<td>Fully Diluted Shares</td>
<td>65,574,675</td>
</tr>
<tr>
<td>Recent Financing @ $0.75 ($0.92 warrant)</td>
<td>$4.5M CAD</td>
</tr>
<tr>
<td>Board and Management Ownership</td>
<td>35%</td>
</tr>
</tbody>
</table>

As at January 28, 2017. Also trading on OTC and FSE.
CONTACT

Corporate
211 - 175 Hargrave St.
Winnipeg, Manitoba
Canada R3C 3R8
E info@3dsignatures.com
T 204 582 0922
F 204 666 4098

Investor Relations
Stephen Kilmer
E stephen.kilmer@3dsignatures.com
T 647-872-4849

Hugh Rogers
VP Corporate Finance
E investors@3dsignatures.com
T 604.250.6162
Genomic imaging for precision medicine